Evidence map›Paper›PMID 41579284›Full record

ArticleDiscover oncology2026

Efficacy and safety of octreotide versus somatostatin therapy after CRS + HIPEC in patients with peritoneal carcinomatosis.

Bing Li, Zhong-He Ji, Gang Liu, Yang Yu, Yan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bing LiDepartment of Oncology Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No.168 Litang Road, Changping District, Beijing, 102218, P. R. China.
Zhong-He JiDepartment of Oncology Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No.168 Litang Road, Changping District, Beijing, 102218, P. R. China.
Gang LiuDepartment of Oncology Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No.168 Litang Road, Changping District, Beijing, 102218, P. R. China.
Yang YuDepartment of Oncology Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No.168 Litang Road, Changping District, Beijing, 102218, P. R. China.
Yan LiDepartment of Oncology Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No.168 Litang Road, Changping District, Beijing, 102218, P. R. China. liyansd2@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aimed to compare the efficacy and safety of perioperative somatostatin versus octreotide in peritoneal carcinomatosis (PC) patients after cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC).

methodsPeritoneal cancer patients treated with CRS + HIPEC were divided into two groups (somatostatin group and octreotide group). The postoperative gastric drainage volume, levels of inflammatory factors, perioperative safety and adverse effects were compared between two groups.

resultsThere were 48 (54.5%) patients in the somatostatin group and 40 (45.4%) in the octreotide group. There was no statistically significant difference in the postoperative gastric drainage volume between two groups. The median time to exhaust and defecation (7 d) was comparable between two groups (3-14 d in the somatostatin group and 4-13 d in the octreotide group). There were significant differences in the serum amylase level on postoperative day 3 (P = 0.044), and white blood cell level and neutrophil percentage at every monitoring time. The serious adverse events (SAEs) were similar and there were no long-term follow-up results between two groups.

conclusionsSomatostatin and octreotide analogues appear to decrease the duration of enterocutaneous fistulas, but their application in PC patients after CRS + HIPEC might reduce SAEs.

Indexed as

Cytoreductive surgeryHyperthermic intraperitoneal chemotherapyOctreotidePeritoneal carcinomaSerious adverse eventsSomatostatin

Identifiers

PMID41579284
PMCPMC12913825

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.